Effects of Interferon on Melanoma Growth
Author Information
Author(s): P. Hersey, E. Hasic, M. MacDonald, A. Edwards, A. Spurling, A.S. Coates, G.W. Milton, W.H. McCarthy
Primary Institution: Kanematsu Memorial Institute, Sydney Hospital
Hypothesis
Can recombinant leukocyte interferon (rIFN-aA) effectively treat patients with metastatic melanoma?
Conclusion
The study found that rIFN-aA can lead to complete remission in some melanoma patients, but further research is needed to identify which patients may benefit most.
Supporting Evidence
- Two patients achieved complete remission after treatment with rIFN-aA.
- Stable disease was observed in two additional patients.
- Side effects were common, with fatigue being the most reported.
Takeaway
This study tested a medicine called interferon on people with skin cancer. Some people got better, but more research is needed to find out who will respond best.
Methodology
Patients received rIFN-aA via intramuscular injection in escalating doses, and their immune responses were monitored through various tests.
Potential Biases
Potential bias due to the small number of evaluable patients and the subjective nature of some assessments.
Limitations
The study had a small sample size and included patients with varying performance statuses, which may affect the generalizability of the results.
Participant Demographics
The study included 20 patients with metastatic melanoma, varying in age and previous treatment history.
Statistical Information
P-Value
<0.05
Confidence Interval
95% confidence levels 3.4-39.6%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website